

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 January 2024 (25.01.2024)



(10) International Publication Number
WO 2024/020084 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 417/14 (2006.01)
C07D 471/04 (2006.01) A61P 29/00 (2006.01)
C07D 519/00 (2006.01) A61K 31/437 (2006.01)

(21) International Application Number:

PCT/US2023/028124

(22) International Filing Date:

19 July 2023 (19.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/390,888 20 July 2022 (20.07.2022) US

(71) Applicants: BRISTOL-MYERS SQUIBB COMPANY

[US/US]; Rte. 206 & Province Line Road, Princeton,
New Jersey 08543 (US). CELGENE CORPORATION
[US/US]; 86 Morris Ave., Summit, New Jersey 07901 (US).

(72) Inventors: RASMUSSEN, Timothy; c/o Celgene Corpora-

tion, 86 Morris Ave., Summit, New Jersey 07901 (US).
DAVIES, Geraint; c/o Celgene Corporation, 86 Morris
Ave., Summit, New Jersey 07901 (US). GORMISKY,
Paul; c/o Celgene Corporation, 86 Morris Ave., Summit,
New Jersey 07901 (US). MA, Rulin; c/o Celgene Corpora-
tion, 86 Morris Ave., Summit, New Jersey 07901 (US).
ELLIS, John Michael; c/o Celgene Corporation, Route
206 and Province Line Road, Princeton, New Jersey 08543
(US). HU, Lingbowei; c/o Bristol-Myers Squibb Compa-
ny, Rte. 206 & Province Line Road, Princeton, New Jersey
08543 (US). SIU, Tony; c/o Bristol-Myers Squibb Compa-
ny, Rte. 206 & Province Line Road, Princeton, New Jer-
sey 08543 (US). VAN DER MEI, Farid; c/o Bristol-My-
ers Squibb Company, Rte. 206 & Province Line Road,
Princeton, New Jersey 08543 (US). HAGER, Harry; c/o
Bristol-Myers Squibb Company, Rte. 206 & Province Line
Road, Princeton, New Jersey 08543 (US). MENG, Yilin;
c/o Bristol-Myers Squibb Company, Rte. 206 & Province
Line Road, Princeton, New Jersey 08543 (US).

(74) Agent: SCARR, Rebecca B. et al.; McNeill Baur PLLC,

125 Cambridge Park Drive, Suite 301, Cambridge, Massa-
chusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4

(57) Abstract: Provided herein are compounds and compositions thereof for modulating IRAK4. In some embodiments, the compounds and compositions are provided for treatment of inflammatory or autoimmune diseases.

WO 2024/020084 A1